Back

Patients with atrial fibrillation treated with apixaban are less likely to discontinue study drug when compared with warfarin: insights from the ARISTOTLE trial

28 August 2016 (14:00 - 18:00)
Organised by:
Congress Presentation Part of: Poster session 3 - Anticoagulation in atrial fibrillation III Atrial fibrillation (AF) ESC Premium Access ESC Congress 2016

About the speaker

Photo
Professor Denis Xavier

St John's Medical College Hospital, Bangalore (India)

24 More presentations in this session

Presentation thumbnail
Doctor C. Gatti (Ravenna, IT)
Abstract Slides
Presentation thumbnail
Doctor D. Iglesias (Santiago de Compostela, ES)
Abstract Slides
Presentation thumbnail
Doctor J. Wieczorek (Katowice, PL)
Abstract Slides
Presentation thumbnail
Associate Professor A. Parwani (Berlin, DE)
Presentation thumbnail
Doctor P. Chan (London, GB)
Abstract Slides

Access the full session

Session thumbnail
Poster session 3 - Anticoagulation in atrial fibrillation III

The Event

Event poster

ESC Congress 2016

28 August 2016 14:00 CET
You may be interested in
thumbnail
Congress Presentation
Adherence and treatment satisfaction among atrial fibrillation patients treated with VKAs versus NOACs: real-world data from a single-center cohort
12 April 2026
thumbnail
Congress Presentation
Apixaban 2.5 mg twice daily is effective and safe for patients with atrial fibrillation and combinations of advanced age, low body weight, and elevated creatinine: insights from ARISTOTLE
2 September 2019
thumbnail
Webinar
How to manage elderly patients with atrial fibrillation and multiple comorbidities
12 November 2021
thumbnail
Congress Session
Update on antiarrhythmic therapy
31 March 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources